July 2025 in “International Journal of Trichology” Intralesional methotrexate and triamcinolone acetonide are more effective than Vitamin D3 for treating alopecia areata.
June 2025 in “British Journal of Dermatology” Certain hair and scalp features can predict the severity of alopecia areata.
June 2025 in “International Journal of Science and Research (IJSR)” Tofacitinib effectively promotes hair regrowth in alopecia areata with minimal side effects.
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Etrasimod is safe but not effective for severe alopecia areata, though it may help milder cases.
May 2025 in “Journal of Pharmacy And Bioallied Sciences” Tofacitinib effectively promotes hair regrowth in children with alopecia areata, but more research on long-term safety is needed.
April 2025 in “International Journal of Dermatology” JAK inhibitors effectively reduce alopecia areata symptoms in Black patients.
April 2025 in “Anais Brasileiros de Dermatologia” Abrocitinib effectively treats severe alopecia areata with significant improvement and no side effects.
Bempikibart may help regrow hair in people with alopecia areata.
April 2025 in “International Journal of Homoeopathic Sciences” Carcinosin, a homeopathic remedy, helped a young girl with alopecia areata regrow hair and reduce psychological symptoms.
March 2025 in “Indian Journal of Dermatology Venereology and Leprology” Tofacitinib is effective for treating alopecia totalis and universalis, with some patients experiencing significant hair regrowth.
March 2025 in “Clinical and Experimental Dermatology” Older patients without prior JAK inhibitor treatment respond best to tofacitinib for alopecia areata.
Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.
February 2025 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Deucravacitinib helped a man regrow hair and improve psoriasis.
February 2025 in “PubMed” Switching JAK inhibitors can lead to significant hair regrowth in severe alopecia cases.
January 2025 in “Dermatologic Therapy” Baricitinib works better for alopecia areata in patients not previously treated with tofacitinib.
January 2025 in “International Journal of Trichology” Combining DPCP with PRP doesn't improve hair regrowth in alopecia areata.
January 2025 in “Figshare” Compound glycyrrhizin combined with conventional treatments effectively and safely promotes hair regrowth in alopecia areata patients.
January 2025 in “Figshare” Compound glycyrrhizin with conventional treatments is effective and safe for promoting hair regrowth in alopecia areata.
December 2024 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Deucravacitinib helped a man regrow hair significantly.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.
November 2024 in “Journal of the Philippine Dermatological Society” Combining methotrexate and corticosteroids can effectively regrow hair in severe alopecia areata.
October 2024 in “Zagazig University Medical Journal” Transdermal delivery using a fractional CO2 laser is more effective for treating alopecia areata than injections.
October 2024 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.
June 2024 in “British Journal of Dermatology” Alopecia areata greatly affects quality of life, especially mental health, and newer assessment tools better capture this impact than older ones.
June 2024 in “Australasian Journal of Dermatology” Tofacitinib is safe and effective for treating moderate-to-severe alopecia areata.
May 2024 in “JEADV Clinical Practice” A change in SALT scores of 42 or 43 indicates meaningful improvement in alopecia areata treatment.
May 2024 in “Journal of cosmetic dermatology” Tofacitinib is an effective and safe treatment for alopecia areata.
Baricitinib effectively promotes hair regrowth in severe alopecia with minimal side effects.
April 2024 in “Frontiers in medicine” Alopecia Areata significantly lowers quality of life and current treatments are inadequate, highlighting a need for better therapies and standardized treatment protocols.
April 2024 in “Frontiers in pharmacology” Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.